210 related articles for article (PubMed ID: 21377481)
1. The role of optimal control in assessing the most cost-effective implementation of a vaccination programme: HPV as a case study.
Brown VL; Jane White KA
Math Biosci; 2011 Jun; 231(2):126-34. PubMed ID: 21377481
[TBL] [Abstract][Full Text] [Related]
2. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
Westra TA; Daemen T; Postma MJ; Wilschut JC
Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
[TBL] [Abstract][Full Text] [Related]
3. The economic impact of HPV vaccines: not just cervical cancer.
Myers ER
Am J Obstet Gynecol; 2008 May; 198(5):487-8. PubMed ID: 18455522
[No Abstract] [Full Text] [Related]
4. Cost-utility analysis of vaccination against HPV in Israel.
Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J
Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844
[TBL] [Abstract][Full Text] [Related]
5. A brief history of economic evaluation for human papillomavirus vaccination policy.
Beutels P; Jit M
Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
[TBL] [Abstract][Full Text] [Related]
6. Cost–effectiveness of catch-up programs in human papillomavirus vaccination.
de Peuter MA; Littlewood KJ; Annemans L; Largeron N; Quilici S
Expert Rev Vaccines; 2010 Oct; 9(10):1187-201. PubMed ID: 20923269
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of human papilloma virus vaccination in Iceland.
Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
9. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
Ault K; Reisinger K
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S26-8. PubMed ID: 18162242
[TBL] [Abstract][Full Text] [Related]
10. The HPV vaccination strategy: could male vaccination have a significant impact?
Brown V; White KA
Comput Math Methods Med; 2010 Sep; 11(3):223-37. PubMed ID: 20582762
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
12. [Developments in HPV vaccination].
de Melker H; Kenter G; van Rossum T; Conyn-van Spaendonck M
Ned Tijdschr Geneeskd; 2012; 156(47):A5410. PubMed ID: 23171565
[TBL] [Abstract][Full Text] [Related]
13. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
[TBL] [Abstract][Full Text] [Related]
14. Global human papillomavirus vaccination: can it be cost-effective?
Crosbie EJ
BJOG; 2012 Jan; 119(2):125-8. PubMed ID: 22168760
[No Abstract] [Full Text] [Related]
15. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
16. Vaccination against HPV: indications for women and the impact on the cervical screening programme.
Heideman DA; Snijders PJ; Berkhof J; Verheijen RH; Helmerhorst TJ; Meijer CJ
BJOG; 2008 Jul; 115(8):938-46. PubMed ID: 18651878
[TBL] [Abstract][Full Text] [Related]
17. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
[TBL] [Abstract][Full Text] [Related]
18. Anti-HPV vaccination: a review of recent economic data for Italy.
Mennini FS; Costa S; Favato G; Picardo M
Vaccine; 2009 May; 27 Suppl 1():A54-61. PubMed ID: 19480963
[TBL] [Abstract][Full Text] [Related]
19. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
[TBL] [Abstract][Full Text] [Related]
20. Challenges of implementing human papillomavirus (HPV) vaccination policy.
Raffle AE
BMJ; 2007 Aug; 335(7616):375-7. PubMed ID: 17717366
[No Abstract] [Full Text] [Related]
[Next] [New Search]